Skip to search formSkip to main contentSkip to account menu

RO4987655

Known as: MEK Inhibitor RO4987655 
An orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

CH 4987655

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
MAPK pathway activation is frequently observed in human malignancies, including melanoma, and is associated with sensitivity to… 
2017
2017
Marcadores moleculares predictivos de respuesta en pacientes con tumores sólidos avanzados tratados con inhibidores de mek y raf dentro de estudios fase i
La via de RAS/RAF/MEK/ERK proteinas quinasas activadas por mitogenos (MAPK) esta implicada en la proliferacion, diferenciacion… 
2015
2015
Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance
Although mitogen-activated protein kinase kinase (MEK) is a key signaling molecule and a negative regulator of insulin action, it… 
2014
2014
Phase I and pharmacokinetics/pharmacodynamics (PK/PD) study of MEK inhibitor, RO4987655, in Japanese patients with advanced solid tumors.
116 Background: RO4987655 is an oral and selective inhibitor of MEK, a key enzyme of the MAPK signaling pathway. This was a phase… 
2012
2012
developmental therapeutics 438 O PHASE II ACTIVITY OF THE HSP 90 INHIBITOR AUY 922 IN PATIENTS WITH ALK-REARRANGED ( ALK + ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER ( NSCLC )
E. Felip1, E. Carcereny2, F. Barlesi3, L. Gandhi4, L.V. Sequist5, S-W. Kim6, H.J. M. Groen7, B. Besse8, D-W. Kim9, E. Smit10, M… 
2012
2012
243 Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors
2009
2009
Cancer Therapy : Clinical The Safety , Tolerability , Pharmacokinetics , and Pharmacodynamics of Single Oral Doses of CH 4987655 in Healthy Volunteers : Target Suppression Using a Biomarker
Purpose:CH4987655 (RO4987655) is an orally active and highly selective small-molecule MEK inhibitor. It potently inhibits mitogen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)